Spero Therapeutics, Inc. announced that Satyavrat “Sath” Shukla, Spero's current Chief Financial Officer and Treasurer, will serve as Spero's Chief Executive Officer, effective August 1, 2023. Mr. Shukla will succeed Spero's current CEO and President, Ankit Mahadevia, M.D., who will become Chairman of the Board of Directors, effective August 1, 2023. Mr. Shukla brings more than two decades of strategic and financial leadership experience to the role of CEO, including the last three years as Spero's CFO and Treasurer.

During his tenure at Spero, he has led all aspects of the Company's finance, accounting, and business development functions, and has played an instrumental role in securing strategic investments and licensing agreements from GSK and Pfizer Inc.